References
- Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–719.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
- Halloy F, Biscans A, Bujold KE, et al. Innovative developments and emerging technologies in RNA therapeutics. RNA Biol. 2022;19(1):313–332.
- Anthony K. RNA-based therapeutics for neurological diseases. RNA Biol. 2022;19(1):176–190.
- Malard F, Mackereth CD, Campagne S. Principles and correction of 5’-splice site selection. RNA Biol. 2022;19(1):943–960.
- Wang X, Hua J, Li J, et al. Mechanisms of non-coding RNA-modulated alternative splicing in cancer. RNA Biol. 2022;19(1):541–547.
- Rouf NZ, Biswas S, Tarannum N, et al. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biol. 2022;19(1):386–410.
- Ghosh A, Myacheva K, Riester M, et al. Chimeric oligonucleotides combining guide RNA and single-stranded DNA repair template effectively induce precision gene editing. RNA Biol. 2022;19(1):588–593.
- Sales Conniff A, Encalada G, Patel S, et al. Poly(I:C) transfection induces a pro-inflammatory cascade in murine mammary carcinoma and fibrosarcoma cells. RNA Biol. 2022;19(1):841–851.
- Gangopadhyay S, Gore KR. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biol. 2022;19(1):452–467.
- Holm A, Hansen SN, Klitgaard H, et al. Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases. RNA Biol. 2022;19(1):594–608.
- Bakowski K, Vogel S. Evolution of complexity in non-viral oligonucleotide delivery systems: from gymnotic delivery through bioconjugates to biomimetic nanoparticles. RNA Biol. 2022;19(1):1256–1275.
- Kilikevicius A, Wang J, Shen X, et al. Difficulties translating antisense-mediated activation of Frataxin expression from cell culture to mice. RNA Biol. 2022;19(1):364–372.
- Kakouri AC, Koutalianos D, Koutsoulidou A, et al. Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights. RNA Biol. 2022;19(1):507–518.
- Eyileten C, Wicik Z, Simões SN, et al. Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19. RNA Biol. 2022;19(1):963–979.
- Amweg A, Tusup M, Cheng P, et al. The A to I editing landscape in melanoma and its relation to clinical outcome. RNA Biol. 2022;19(1):996–1006.
- Wang S, Wang S, Zhang X, et al. Comprehensive analysis of prognosis-related alternative splicing events in ovarian cancer. RNA Biol. 2022;19(1):1007–1018.
- Xu Y, Huang C. Progress and application of epitranscriptomic m(6)A modification in gastric cancer. RNA Biol. 2022;19(1):885–896.
- Wallis N, Oberman F, Shurrush K, et al. Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA Biol. 2022;19(1):26–43.
- Shirazi-Tehrani E, Chamasemani A, Firouzabadi N, et al. ncRNAs and polyphenols: new therapeutic strategies for hypertension. RNA Biol. 2022;19(1):575–587.